Patents by Inventor Yosi Gozlan

Yosi Gozlan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240139318
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Application
    Filed: August 21, 2023
    Publication date: May 2, 2024
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • Publication number: 20240109952
    Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.
    Type: Application
    Filed: December 13, 2023
    Publication date: April 4, 2024
    Applicant: KAHR Medical Ltd.
    Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
  • Publication number: 20240101669
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Application
    Filed: August 11, 2023
    Publication date: March 28, 2024
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • Publication number: 20240075137
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Application
    Filed: May 23, 2023
    Publication date: March 7, 2024
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • Patent number: 11897937
    Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: February 13, 2024
    Assignee: KAHR Medical Ltd.
    Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
  • Publication number: 20240025973
    Abstract: The present invention is directed to PVRIG polypeptides and their uses.
    Type: Application
    Filed: September 1, 2023
    Publication date: January 25, 2024
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Amir Toporik, Yossef Kliger, Ofer Levy, Arthur Machlenkin, Sergey Nemzer, Yair Benita, Amit Novik
  • Publication number: 20240010700
    Abstract: PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-41BBL fusion protein, host-cells expressing the PD1-41BBL fusion protein and methods of use thereof.
    Type: Application
    Filed: June 21, 2023
    Publication date: January 11, 2024
    Applicant: KAHR Medical Ltd.
    Inventors: Mark L. TYKOCINSKI, Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
  • Patent number: 11795220
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: October 24, 2023
    Assignee: COMPUGEN LTD.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • Patent number: 11795209
    Abstract: The present invention is directed to PVRIG polypeptides and their uses.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: October 24, 2023
    Assignee: COMPUGEN LTD.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Amir Toporik, Yossef Kliger, Ofer Levy, Arthur Machlenkin, Sergey Nemzer, Yair Benita, Amit Novik
  • Publication number: 20230242611
    Abstract: MAGE-A1 specific T cell receptors (TCRs) are provided. Accordingly, there is provided a TCR comprising a TCR ? chain as set forth in SEQ ID NO: 1 having at least one mutation at an amino acid position selected from the group consisting of S189, G125, W55 and Y56; and/or a TCR ? chain as set forth in SEQ ID NO: 2 having at least one mutation at an amino acid position selected from the group consisting of S32, S109 and T63, the TCR binds a MAGE-A1 peptide as set forth in SEQ ID NO: 25. Also provided are polynucleotides encoding the TCR and T cells expressing same and methods of use thereof.
    Type: Application
    Filed: February 9, 2023
    Publication date: August 3, 2023
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Rachel Lea EISENBACH, David BASSAN, Yosi GOZLAN, Esther TZEHOVAL, Nir FRIEDMAN, Erez GREENSTEIN
  • Patent number: 11702458
    Abstract: PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-41BBL fusion protein, host-cells expressing the PD1-41BBL fusion protein and methods of use thereof.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: July 18, 2023
    Assignee: KAHR Medical Ltd.
    Inventors: Mark L. Tykocinski, Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
  • Patent number: 11701424
    Abstract: Anti-PVRIG and anti-TIGIT antibodies are provided.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: July 18, 2023
    Assignee: COMPUGEN LTD.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Maya Kotturi, Hsin-Yuan Cheng, Kyle Hansen, David Nisim Giladi, Einav Safyon, Eran Ophir, Leonard Presta, Richard Theolis, Radhika Desai, Patrick Wall
  • Publication number: 20230220040
    Abstract: PD1-CD70 fusion proteins are provided. Accordingly, there is provided a PD1-CD70 fusion protein comprising a single amino acid linker between the PD1 and the CD70. Also there is provided a PD1-CD70 fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-CD70 fusion protein, host-cells expressing the PD1-CD70 fusion protein and methods of use thereof.
    Type: Application
    Filed: January 26, 2023
    Publication date: July 13, 2023
    Applicant: KAHR Medical Ltd.
    Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
  • Patent number: 11623955
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: April 11, 2023
    Assignee: COMPUGEN LTD.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • Patent number: 11566060
    Abstract: PD1-CD70 fusion proteins are provided. Accordingly, there is provided a PD1-CD70 fusion protein comprising a single amino acid linker between the PD1 and the CD70. Also there is provided a PD1-CD70 fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-CD70 fusion protein, host-cells expressing the PD1-CD70 fusion protein and methods of use thereof.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: January 31, 2023
    Assignee: KAHR Medical Ltd.
    Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
  • Publication number: 20220211758
    Abstract: The present invention relates to methods and systems for increasing the affinity of a T cell receptor (TCR) to its ligand by subjecting the TCR gene to somatic hypermutation. The present invention further relates to use of affinity maturated TCRs to create T cells reactive against a selected antigen.
    Type: Application
    Filed: January 13, 2022
    Publication date: July 7, 2022
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Rachel Lea EISENBACH, Yosi GOZLAN, Esther TZEHOVAL
  • Publication number: 20220204586
    Abstract: SIRPalpha-CD70 fusion proteins are provided. Accordingly, there is provided a SIRPalpha-CD70 fusion protein comprising a single amino acid linker between the SIRPalpha and the CD70. Also there is provided a SIRPalpha-CD70 fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-CD70 fusion protein, host-cells expressing the SIRPalpha-CD70 fusion protein and methods of use thereof.
    Type: Application
    Filed: March 16, 2022
    Publication date: June 30, 2022
    Applicant: KAHR Medical Ltd.
    Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
  • Patent number: 11299530
    Abstract: SIRPalpha-CD70 fusion proteins are provided. Accordingly, there is provided a SIRPalpha-CD70 fusion protein comprising a single amino acid linker between the SIRPalpha and the CD70. Also there is provided a SIRPalpha-CD70 fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-CD70 fusion protein, host-cells expressing the SIRPalpha-CD70 fusion protein and methods of use thereof.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: April 12, 2022
    Assignee: KAHR Medical Ltd.
    Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
  • Patent number: 11273178
    Abstract: The present invention relates to methods and systems for increasing the affinity of a T cell receptor (TCR) to its ligand by subjecting the TCR gene to somatic hypermutation. The present invention further relates to use of affinity maturated TCRs to create T cells reactive against a selected antigen.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: March 15, 2022
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Rachel Lea Eisenbach, Yosi Gozlan, Esther Tzehoval
  • Patent number: 11220542
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: January 11, 2022
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis